암 단일클론항체 시장 : 유형, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Cancer Monoclonal Antibodies Market was valued at USD 69.87 billion in 2023, expected to reach USD 78.60 billion in 2024, and is projected to grow at a CAGR of 12.89%, to USD 163.28 billion by 2030.

Cancer monoclonal antibodies (mAbs) represent a pivotal advancement in oncology, marked by their targeted therapeutic approach which specifically attacks cancer cells while sparing healthy tissues. Their necessity arises from the growing prevalence of cancer and the need for more effective, less toxic treatment alternatives compared to traditional options like chemotherapy and radiation. The application of mAbs spans numerous cancer types, with significant utility in breast, colorectal, non-Hodgkin's lymphoma, and lung cancers. End-use scope mainly involves hospitals, specialty clinics, and research institutes engaged in precision medicine. Market insights reveal robust growth driven by technological advancements in antibody engineering, rising public and private R&D investments, and increased regulatory approvals for new therapies. Opportunities abound with the integration of mAbs in personalized medicine, harnessing companion diagnostics for patient stratification, and utilizing bispecific monoclonal antibodies to target multiple antigens simultaneously. Key challenges include high development costs, complex manufacturing processes, and stringent regulatory requirements, which can impede smaller players from entering the market. Market growth is also hindered by limited awareness and access in emerging regions, alongside biosimilar competition decreasing monopoly pricing potential. Innovations poised for business growth lie in improving antibody-drug conjugates, leveraging artificial intelligence for drug discovery, and exploring immune checkpoint inhibitors combination therapies. To capitalize on emerging opportunities, companies should focus on strategic collaborations, expand clinical trials globally, and advocate for favorable reimbursement policies to enhance treatment accessibility. The market is dynamic, characterized by rapid technological progress and evolving regulatory landscapes, necessitating agile strategies and continuous adaptation. By aligning with these trends and tackling developmental and operational hurdles, stakeholders can leverage the expanding therapeutic and commercial potential of cancer monoclonal antibodies effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of different cancers worldwide
  • Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
  • Increasing drug approvals along with a robust pipeline
• Market Restraints
  • Surging number of withdrawals of monoclonal antibodies
• Market Opportunities
  • Increasing clinical trials of newly developed monoclonal antibodies
  • Collaborative approach for development of cancer monoclonal antibodies
• Market Challenges
  • Regulatory and technical complications associated with manufacture of monoclonal antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Monoclonal Antibodies Market

A detailed market share analysis in the Cancer Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Monoclonal Antibodies Market

A strategic analysis of the Cancer Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen, Inc., Astrazeneca PLC, Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol Myers Squibb Co., Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GSK PLC, Incyte Corporation, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis AG, Pfizer Inc., Qiagen N.V., Sanofi S.A., Sartorius AG, Seagen Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chimeric, Human, Humanized, and Murine.
• Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, and Melanoma.
• Based on End-user, market is studied across Hospitals, Research Institutes, and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of different cancers worldwide
    • 5.1.1.2. Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
    • 5.1.1.3. Increasing drug approvals along with a robust pipeline
  • 5.1.2. Restraints
    • 5.1.2.1. Surging number of withdrawals of monoclonal antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing clinical trials of newly developed monoclonal antibodies
    • 5.1.3.2. Collaborative approach for development of cancer monoclonal antibodies
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and technical complications associated with manufacture of monoclonal antibodies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Monoclonal Antibodies Market, by Type

• 6.1. Introduction
• 6.2. Chimeric
• 6.3. Human
• 6.4. Humanized
• 6.5. Murine

7. Cancer Monoclonal Antibodies Market, by Application

• 7.1. Introduction
• 7.2. Blood Cancer
• 7.3. Breast Cancer
• 7.4. Colorectal Cancer
• 7.5. Liver Cancer
• 7.6. Lung Cancer
• 7.7. Melanoma

8. Cancer Monoclonal Antibodies Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Research Institutes
• 8.4. Research Laboratories

9. Americas Cancer Monoclonal Antibodies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Monoclonal Antibodies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Agilent Technologies, Inc.
• 3. Amgen, Inc.
• 4. Astrazeneca PLC
• 5. Bayer AG
• 6. Becton, Dickinson and Company
• 7. Bio-Rad Laboratories, Inc.
• 8. Bristol Myers Squibb Co.
• 9. Celldex Therapeutics, Inc.
• 10. Eli Lilly and Company
• 11. F. Hoffmann-La Roche AG
• 12. Gilead Sciences, Inc.
• 13. GSK PLC
• 14. Incyte Corporation
• 15. Johnson & Johnson
• 16. Merck & Co.
• 17. Merck KGaA
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Qiagen N.V.
• 21. Sanofi S.A.
• 22. Sartorius AG
• 23. Seagen Inc.
• 24. Takara Bio Inc.
• 25. Thermo Fisher Scientific Inc.